Alzheimer's disease

Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.  The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in...

Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote" on its marketing application for its controversial Alzheimer's drug aducanumab. "While we are disappointed...

​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related: Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates. The analysis comes from...

Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild...

Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference.  The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and...

With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition. Companies like Roche Holdings AG (OTC: RHHBY) and Eli Lilly And Co (NYSE: LLY) are already lining up...

Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease.  The peer-reviewed article was co-authored by...

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such as StockTwits throughout the day. Cassava Sciences is trading up 25.94% at $58.07 Tuesday at market close. Cassava...

Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN trial data for its Alzheimer’s disease trial. The company stated co-primary endpoints were...

Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is designed to neutralize beta-amyloid plaques seen as a driver behind brain cell death. The Company said that the U.S....

Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease.  A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year-end. Phase 3...

Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path for its planned clinical development of AL002, the Company says. AL002...

Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab is an anti-amyloid beta (Aβ) protofibril antibody. In March 2014, Eisai and Biogen Inc (NASDAQ: BIIB)...

It's been about four months since Biogen, Inc. (NASDAQ: BIIB) received approval for its controversial Alzheimer's treatment Aduhelm. The initial broad approval was later narrowed by the FDA. The "Aduhelm opportunity" for the biopharma is underappreciated, an analyst said Thursday...

B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data "reinvigorate" investor confidence.  The Company announced a pre-planned interim analysis of an ongoing open-...